Epithelial-mesenchymal transition-converted tumor cells can induce T-cell apoptosis through upregulation of programmed death ligand 1 expression in esophageal squamous cell carcinoma

Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial

(2017) Toshihiro Kudo et al.   LANCET ONCOLOGY

Immunotherapy for Esophageal Squamous Cell Carcinoma

(2017) Takashi Kojima et al.   Current Oncology Reports

Dual Faces of IFN  in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity

(2016) M. Mandai et al.   CLINICAL CANCER RESEARCH

Updated results for the advanced esophageal carcinoma cohort of the phase Ib KEYNOTE-028 study of pembrolizumab (MK-3475).

(2016) Toshihiko Doi et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma

(2016) Chan-Young Ock et al.   Oncotarget

Regulation of PD-L1: a novel role of pro-survival signalling in cancer

(2015) J. Chen et al.   ANNALS OF ONCOLOGY

CXCL10 Expression Status is Prognostic in Patients with Advanced Thoracic Esophageal Squamous Cell Carcinoma

(2015) Yusuke Sato et al.   ANNALS OF SURGICAL ONCOLOGY

IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer

(2015) K Abiko et al.   BRITISH JOURNAL OF CANCER

PDL1 Regulation by p53 via miR-34

(2015) Maria Angelica Cortez et al.   JNCI-Journal of the National Cancer Institute

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma

(2015) Patcharee Ritprajak et al.   ORAL ONCOLOGY

PDL1 Regulation by p53 via miR-34

(2015) Maria Angelica Cortez et al.   JNCI-Journal of the National Cancer Institute

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups

(2015) Lars Henning Schmidt et al.   PLoS One

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

(2014) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

The Common  -Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Induce the Expression of Programmed Death-1 and Its Ligands

(2014) A. L. Kinter et al.   JOURNAL OF IMMUNOLOGY

Signaling mechanisms of the epithelial-mesenchymal transition

(2014) D. M. Gonzalez et al.   Science Signaling

Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression

(2014) Limo Chen et al.   Nature Communications

PD-L1 Expression in Triple-Negative Breast Cancer

(2014) E. A. Mittendorf et al.   Cancer Immunology Research

Oesophageal carcinoma

(2013) Arjun Pennathur et al.   LANCET

Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial

(2013) Thomas Crosby et al.   LANCET ONCOLOGY

Anti-PD1 antibody: a new approach to treatment of lymphomas

(2013) Emmanuel Bachy et al.   LANCET ONCOLOGY

A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application

(2013) Taku Okazaki et al.   NATURE IMMUNOLOGY

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody

(2012) E. J. Lipson et al.   CLINICAL CANCER RESEARCH

Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer

(2012) P. van Hagen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Classification of epithelial–mesenchymal transition phenotypes in esophageal squamous cell carcinoma is strongly associated with patient prognosis

(2011) Chang Ohk Sung et al.   MODERN PATHOLOGY

Cancer immunotherapy comes of age

(2011) Ira Mellman et al.   NATURE

The PD-1 pathway in tolerance and autoimmunity

(2010) Loise M. Francisco et al.   IMMUNOLOGICAL REVIEWS